EMC Capital Management Has $208,000 Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

EMC Capital Management decreased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 44.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,893 shares of the biotechnology company’s stock after selling 19,422 shares during the period. EMC Capital Management’s holdings in Ironwood Pharmaceuticals were worth $208,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 21.8% during the first quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock valued at $170,031,000 after purchasing an additional 3,487,821 shares during the period. Armistice Capital LLC raised its holdings in shares of Ironwood Pharmaceuticals by 64.9% during the fourth quarter. Armistice Capital LLC now owns 5,700,000 shares of the biotechnology company’s stock valued at $65,208,000 after purchasing an additional 2,244,000 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 40.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 4,235,580 shares of the biotechnology company’s stock valued at $36,892,000 after purchasing an additional 1,226,377 shares during the period. Kynam Capital Management LP acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at about $14,154,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Ironwood Pharmaceuticals by 4.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,288,653 shares of the biotechnology company’s stock valued at $14,742,000 after purchasing an additional 57,859 shares during the period.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on IRWD. Craig Hallum lowered their target price on shares of Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, May 10th. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $18.40.

Insider Activity

In other news, Director Catherine Moukheibir sold 44,426 shares of the firm’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $6.36, for a total transaction of $282,549.36. Following the sale, the director now owns 84,207 shares in the company, valued at approximately $535,556.52. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, Director Catherine Moukheibir sold 44,426 shares of the firm’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $6.36, for a total transaction of $282,549.36. Following the sale, the director now owns 84,207 shares in the company, valued at approximately $535,556.52. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Julie Mchugh sold 22,766 shares of the firm’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $6.29, for a total transaction of $143,198.14. Following the sale, the director now owns 139,528 shares in the company, valued at approximately $877,631.12. The disclosure for this sale can be found here. Corporate insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD traded down $0.06 on Friday, hitting $6.53. The stock had a trading volume of 1,615,140 shares, compared to its average volume of 3,458,087. Ironwood Pharmaceuticals, Inc. has a 52-week low of $5.47 and a 52-week high of $15.70. The firm has a 50-day moving average of $6.38 and a 200-day moving average of $8.89.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.20). Ironwood Pharmaceuticals had a negative return on equity of 28.45% and a negative net margin of 254.41%. The firm had revenue of $74.90 million during the quarter, compared to analysts’ expectations of $105.75 million. During the same quarter in the prior year, the company earned $0.25 earnings per share. The business’s revenue for the quarter was down 28.0% compared to the same quarter last year. Analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.56 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.